Tools
Tools
Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ , Voysey, M, Oxford COVID Vaccine Trial Group, , Tahmasebi, F and Smith, A (2021) Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 27 (11). pp. 2032-2040. ISSN 1078-8956
|
Text
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection..pdf - Published Version Available under License Creative Commons Attribution. Download (10MB) | Preview |
Abstract
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF<sub>50</sub>) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Oxford COVID Vaccine Trial Group; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Asymptomatic Infections; COVID-19; COVID-19 Vaccines; Cohort Studies; Female; Humans; Immunity, Humoral; Immunization, Secondary; Infection Control; Male; Middle Aged; Patient Acuity; SARS-CoV-2; Treatment Outcome; United Kingdom; Vaccination; Young Adult; 11 Medical and Health Sciences; Immunology |
| Subjects: | R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RM Therapeutics. Pharmacology R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine > RA0440 Study and Teaching. Research |
| Divisions: | Biological & Environmental Sciences (from Sep 19) Computer Science & Mathematics |
| Publisher: | Springer Nature |
| SWORD Depositor: | A Symplectic |
| Date Deposited: | 02 Mar 2023 10:35 |
| Last Modified: | 02 Mar 2023 10:45 |
| DOI or ID number: | 10.1038/s41591-021-01540-1 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/18987 |
 |
View Item |